Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia
January 06, 2022 16:02 ET | Blue Note Therapeutics
SAN FRANCISCO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced...
NEW ATAI-Logo_Primary.png
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
September 09, 2021 16:30 ET | atai Life Sciences
BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
ehave-logo.png
Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave
July 29, 2021 08:30 ET | Ehave
HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances. Ehave...
DBMR Logo.png
Prescription Digital Therapeutics (PDTx) Market Size Hitting New Highs Explored with CAGR of 11.20%, Opportunities, Revenue, Industry Trends and Forecast by 2027
July 14, 2021 10:54 ET | Data Bridge Market Research
SAN FRANCISCO, July 14, 2021 (GLOBE NEWSWIRE) -- Data Bridge Market Research has recently added concise research on the Global Prescription Digital Therapeutics (PDTx) Market report to depict...
ehave-logo.png
Ehave, Inc. To Be One Of Four Main Sponsors At The Third Annual Psytech Summit on July 19th and 20th, 2021
July 02, 2021 08:30 ET | Ehave
MIAMI, July 02, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it will be...
AMR Logo.png
Digital Therapeutics Market Size to Hit $13.80 Billion by 2027, Says Allied Market Research
April 07, 2021 10:55 ET | Allied Market Research
Portland, OR, April 07, 2021 (GLOBE NEWSWIRE) -- As per the report, the global Digital Therapeutics Market was pegged at $2.88 billion in 2019, and is projected to reach $13.80 billion by 2027,...
ehave-logo.png
Psilocybin Data Study Agreement Reached Between Ehave Inc. and Silo Wellness Using Brain Scientific Mapping Neurocap
March 23, 2021 07:00 ET | Ehave
MIAMI, March 23, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors, and Silo Wellness Inc. (CSE: SILO) (“Silo...
AMR Logo.png
Digital Therapeutics Market Size to Hit $13.80 Billion, At 20.5% CAGR, Says Allied Market Research
March 15, 2021 10:25 ET | Allied Market Research
Portland, OR, March 15, 2021 (GLOBE NEWSWIRE) -- Allied Market Research recently published a report, titled, “Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease...
ehave-logo.png
Ehave CEO Benjamin Kaplan to be Featured on Psychedelic Spotlight Segment of New to the Street Airing on NewsMax on Sunday March 14th at 10:00 AM EST and Fox Business March 15th at 7:30 PM EST
March 12, 2021 12:01 ET | Ehave
MIAMI, March 12, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today CEO and...
ehave-logo.png
Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB
March 03, 2021 08:30 ET | Ehave
MIAMI, March 03, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has...